SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Prognostic role of microRNA-31 in various cancers: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.Laryngoscope investigative otolaryngology · 2024Article
- The high expression of miR-31 in lung adenocarcinoma inhibits the malignancy of lung adenocarcinoma tumor stem cells.Biochemistry and biophysics reports · 2021Article
- The Role of miR-31-5p in the Development of Intervertebral Disc Degeneration and Its Therapeutic Potential.Frontiers in cell and developmental biology · 2021Article
- Article
- MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).Thoracic cancer · 2020Article
- miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer.Molecular therapy. Nucleic acids · 2019Article
- Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.Molecular diagnosis & therapy · 2019Article
- MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis.Cancer management and research · 2019Article
- LincRNA-SLC20A1 (SLC20A1) promotes extracellular matrix degradation in nucleus pulposus cells in human intervertebral disc degeneration by targeting the miR-31-5p/MMP3 axis.International journal of clinical and experimental pathology · 2019Article
- Integrating Circulating Immunological and Sputum Biomarkers for the Early Detection of Lung Cancer.Biomarkers in cancer · 2018Article
- MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value.Oncotarget · 2017Article
- miR-31 affects colorectal cancer cells by inhibiting autophagy in cancer-associated fibroblasts.Oncotarget · 2016Article
- Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection.Clinical epigenetics · 2016Article
- Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.OncoTargets and therapy · 2016Article
- MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma.OncoTargets and therapy · 2016Article
- Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools.Molecular biology reports · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, many studies have shown that microRNAs (miRNA) exhibit altered expression levels in various cancers and may play a potential role as diagnostic and prognostic biomarkers of cancers. This meta-analysis was designed to evaluate the exact role of microRNA-31 (miR-31) for survival and discuss the possibility of utilizing miR-31 to predict the prognosis of patients with various human cancers. Electronic literature databases including PubMed, Web of Science, and Embase were searched for articles published until May 2014. The articles only written in English were considered. Data were extracted from studies comparing overall survival (OS), cancer-specific survival (CSS), or postoperative survival (PS) in patients with multiple cancers, which showed higher miR-31 expression than with similar patients. Pooled hazard ratios (HRs) of miR-31 for survival and 95 % confidence intervals (CI) were calculated. Ten studies with a total of 1,648 participants were included for the meta-analysis. For OS, the pooled HRs of higher miR-31 expression in cancers indicated significant predictor poorer survival in general cancers in either univariate analysis (HR=2.34, 95 % CI=1.15-3.52, P<0.05) or multivariate analysis (HR=1.15, 95 % CI=1.04-1.26, P<0.05). For CSS, elevated miR-31 was also a significant predictor to general cancers in multivariate analysis (HR=1.77, 95 % CI=1.06-2.47, P<0.05). And, no association was found between miR-31 expression and PS. In conclusion, the present findings indicate that high miR-31 expression is associated with poor OS and CSS in patients with general cancers and miR-31 may be a useful clinical prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.